Precision without the operating theatre

Replacing an operation with a needle sounds, at first, like a compromise — as though the precision of a theatre procedure has been traded away for convenience. NanoACi, Professor Paul Lee's surgeon-led, non-arthroscopic, needle-delivered, one-stage autologous chondrogenic injection technique, is built on the opposite logic.

Precision here rests on two interlocked mechanisms that are established before the needle approaches the joint. The first is a formal imaging review: MRI findings give the operating surgeon a detailed map of the target anatomy. The second is the retained specialist — Professor Paul Lee reviews those images, selects suitable cases, plans the delivery, and performs it. Neither step has been removed; the operating theatre and the external cell-culture stage have.

'The innovation is not removing the surgeon. It is removing surgical trauma that no longer needs to be there.' That distinction is the foundation of NanoACi's precision claim — and the imaging review that makes targeted delivery possible is where it begins.

MRI review: mapping the joint before the needle moves

Before any biological component is prepared, the Brand Guidelines sequence an explicit clinical logic: case selection, imaging review, preparation, delivery, follow-up. The order is causal, not administrative. Delivery cannot be targeted until the imaging review is complete.

That review centres on MRI. The scan gives Professor Lee a detailed picture of the joint before the needle enters it — the extent and position of the cartilage damage, the surrounding anatomy, and whether a needle-only route to the site is structurally appropriate. This is the formal suitability gate: the all-inclusive NanoACi pathway includes both a mandatory MRI scan and a consultation-with-imaging-review as fixed components, not optional add-ons. For some patients reviewed at this stage, surgery or an alternative pathway remains the right answer; needle delivery is planned only where the anatomy and the defect support it.

The contrast with arthroscopy clarifies why this upstream step carries such weight. A surgeon working arthroscopically has a camera inside the joint, confirming in real time exactly where to act. Without that live intra-operative view, the radiological map must do the equivalent targeting work in advance — and MRI, read by the same surgeon who will perform the delivery, is the instrument that does it. Professor Lee reviews the cross-sectional detail, decides which zone within the joint receives the construct, and plans the needle approach before the session begins. The precision is established at the imaging stage; the needle follows a path that has already been thought through.

The surgeon as the precision instrument

The clinic room is not where NanoACi ends up — it is where it was designed to be. Professor Paul Lee performs the complete procedure in a planned outpatient sitting: blood draw for PRF, auricular cartilage harvest, point-of-care preparation, and needle delivery into the joint. No operating theatre, no general anaesthetic, no overnight admission. The entire sequence takes approximately thirty minutes.

That brevity does not signal reduced rigour. It reflects a preparation model in which the imaging review and delivery plan have been established before the patient takes their seat. The efficiency belongs to the upstream work already done; thirty minutes is what remains once it is complete.

What is preserved in this setting is the surgeon. Professor Paul Lee selects each case, reviews the MRI, prepares the three-component construct, performs the delivery and oversees follow-up. That continuity — one specialist across every stage of the pathway — is a structural feature of how NanoACi was designed, not a consequence of working outside a theatre. The arthroscopic access, the external laboratory stage, the second admission: these are what Professor Lee removed. The anatomical expertise, the delivery judgement, and the knowledge of where within the joint the construct must be placed were kept intact.

For patients familiar with two-stage ACI — two hospital admissions, an external cell-culture interval, and a second arthroscopic procedure — the contrast is structural rather than cosmetic. NanoACi is not a simplified version of that pathway but a different lane entirely: one in which the surgeon's clinical role is unchanged and the procedural infrastructure around it has been reduced to what is genuinely necessary.

Three biological roles through one needle

Three components fulfil a single biological purpose — and all three are prepared from the patient's own body in the same sitting.

Seed. Mytocel MSK cartilage micrografts are the cellular foundation of the construct. Three punches of approximately 2.5 mm are taken from the concha of the ear under local anaesthetic, then mechanically prepared into micrografts at point of care — no enzyme digestion, no external cell-culture stage. The sampling site is itself a deliberate biological choice: gram for gram, auricular cartilage holds greater regenerative potential than the articular cartilage inside a joint, because it is surrounded by a perichondrium rich in chondrogenic progenitor cells. Taking from the ear also leaves the surface being treated entirely undisturbed.

Scaffold. ChondroFiller, a cell-free native type I collagen matrix, provides a structural environment that holds the micrografts in position at the target site and supports the rebuilding process.

Signal. Arthrozheal platelet-rich fibrin, prepared from the patient's own blood during the same session, supplies the growth-factor environment that instructs the micrografts to engage with the surrounding tissue.

Together, these three components address the biological problem that each alone cannot resolve: the cells need something to hold them in place, the scaffold needs cells to do the rebuilding, and both need the signalling cue. As the rationale puts it, 'the fibrin and the collagen hold the cells in place, the cells do the building, the growth factors tell them to.' Combined at point of care, the complete construct is delivered through a single needle to the site the MRI review has already defined — no laboratory interval, no second appointment, one planned procedure from preparation to delivery.

Targeting different joints with the same approach

Joint anatomy varies considerably between the knee, hip, shoulder and ankle — the bony architecture, the access windows, and the depth of the cartilage defect differ in each case. Arthroscopic access is designed around those differences; each joint requires its own port placement, instrument configuration and theatre set-up.

Needle delivery does not carry the same anatomical constraints, precisely because the targeting work has already been done. The pre-procedural MRI review tells Professor Lee where within a given joint the defect sits and which access route suits that patient's anatomy — before the session begins. The needle reaches a confirmed target; it does not navigate by feel.

NanoACi applies across all four joints at the same planned outpatient sitting, with the same three-component construct, prepared and delivered by the same specialist. The flexibility follows directly from moving precision upstream: what changes between a knee case and an ankle case is the MRI-informed delivery plan, not the clinical model itself.

Imaging after delivery: how NanoACi 100 measures what changes

Measuring what changes after delivery is built into the NanoACi protocol as a structural commitment. The NanoACi 100 programme prospectively tracks the first 100 consecutive cases, recording pain scores, functional measures and imaging findings at pre-agreed intervals — with results reported only when the dataset is complete. That discipline follows logically from a technique designed around verified targeting: if pre-procedural imaging maps the defect, structured post-delivery imaging should verify what the intervention produced.

The component-level evidence provides the foundation from which combined-protocol outcomes are being built. ChondroFiller carries published trial evidence against microfracture and more than a decade of clinical use across multiple joints; the micrografts rest on established neural-crest biology; PRF's growth-factor profile is well-characterised in the regenerative medicine literature. NanoACi 100 is the mechanism for establishing whether these individually evidenced components work as designed when combined in a single delivery — a question the programme is measuring with the same rigour applied to planning.

For a patient, the consequence is that follow-up imaging at pre-agreed intervals is not incidental to the pathway — it closes a clinical loop that began before the session. Delivery precision and measurement precision are, by design, the same specialist's responsibility.